Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
  • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
  • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
  • C07C233/14—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
  • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

• the present invention relates to a novel process for preparing (S)-l-[2(S)-(l,3-dihydro-l,3-dioxo-isoindo-2-yl)- l-oxo-3-phenylprcpyl]-1,2,3,4-tetrahydro-2-pyridine- carboxylic acid methyl es»ter which is a useful intermediate in the preparation of [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ] ]-7-[ (1-oxo- 2(S)-thio-3-phenylpropyl)amino]-1,2,3,4,6,7,8,12b- octahydro-6-oxo-pyrido[2,1-a] [2]benzazepine-4-carboxylic acid and [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ] ]-7-[ (l-oxo-2(S)-acetylthio- 3-phen
• the process and intermediates of the present invention provide a novel enantiospecific method for preparing (S)-l- [2(S)-(1,3-dihydro-l,3-dioxo-isoindo-2-yl)-l-oxo-3- phenylpropyl]-1,2,3,4-tetrahydro-2-pyridine-carboxylic acid methyl ester.
• the present invention provides a novel process for preparing (S)-l-[2(S)-(1,3-dihydro-l,3-dioxo-isoindo-2-yl)- l-oxo-3-phenylpropyl]-1,2,3,4-tetrahydro-2-pyridine- carboxylic acid methyl ester comprising the steps of:
• R is hydrogen or trichloroacetyl.
• m refers to a bond that protrudes forward out of the plane of the page
• pharmaceutically acceptable acid addi- tion salts is intended to apply to any non-toxic organic or inorganic acid addition salt of [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ]]-7- [ (l-oxo-2(S)-thio-3-phenylpropy1)amino]-1,2,3,4,6,7,8,12b- octahydro-6-oxo-pyrido[2,l-a] [2]benzazepine-4-carboxylie acid or [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ] ]-7-[ (l-oxo-2(S)-acetylthio-3- phenylpropyl)amino]-l,2,3,4,6,7,8,12b-octahydro-6-oxo- pyrido[2,1-a] [2]benzazepine-4-carboxylic acid or any of its intermediates.
• Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric, and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate, and potassium hydrogen sulfate.
• Illustrative organic acids which form suitable salts include the mono-, di-, and tricarboxylic acids.
• Such acids are for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxy-benzoic, phenylacetic, cinnamic, salicyclic, 2- phenoxy-benzoic, and sulfonic acids such as p- toluenesulfonic acid, methane sulfonic acid and 2- hydroxyethane sulfonic acid.
• Such salts can exist in either a hydrated or substantially anhydrous form.
• pharmaceutically acceptable basic addition salts is intended to apply to any non-toxic organic or inorganic basic addition salts of [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ] ]-7-[ (l-oxo-2(S)-thio-3-phenylpropyl)amino]- 1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1- a] [2]benzazepine-4-carboxylic acid or [4S-[4 ⁇ , 7 ⁇ (R*), 12b ⁇ ] ]-7-[ (l-oxo-2(S)-acetylthio-3-phenylpropyl)amino]- 1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1- a] [2]benzazepine-4-carboxylic acid or any of its intermediates.
• Illustrative bases which form suitable salts include alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium, or barium hydroxides; ammonia, and aliphatic, cyclic, or aromatic organic amines such as methy ⁇ amine, dimethylamine, trimethylamine, triethylamine, diethylamine, isopropyldiethylamine, pyridine and picoline.
• alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium, or barium hydroxides
• ammonia and aliphatic, cyclic, or aromatic organic amines such as methy ⁇ amine, dimethylamine, trimethylamine, triethylamine, diethylamine, isopropyldiethylamine, pyridine and picoline.
• step a cyclohexenone is sequentially contacted with a appropriate chlorinating agent and an appropriate base to give 2-chlorocyclohex-2-en-l-one.
• An appropriate chlorinating agent is one that may provide the proposed 2,3-dichlorocyclohexan-l-one intermediate without giving rise to inconvenient amounts of over chlorination products.
• 2,3-Dichlorocyclohexan-l-one is proposed in the art to be the intermediate in step a. It is intended that the present invention is not limited in any way by the proposal in the art of 2,3- dichlorocyclohexan-1-one as the intermediate in step a.
• An appropriate base is one which assists in the elimination of the 3-position chlorine without the formation of by-product of nucleophilic attack.
• cyclohexenone is contacted with an equimolar amount of an appropriate chlorinating agent.
• the reaction is carried out in a suitable solvent, such as dichloromethane.
• a hindered base such as 2,6- lutidine during the chlorination is advantageous in preventing the formation of over chlorination products.
• the reaction is carried out at temperatures of from -40°C to 20°C, with a temperature of from -5°C to 0°C preferred.
• the product may be isolated from the reaction zone by extraction and evaporation, as is well known in the art.
• the product may be purified by techniques well known in the art, such as chromatography and recrystallization.
• An appropriate chiral auxiliary is one that leads stereoselective reduction of 2-chlorocyclohex-2-en-l-one.
• An appropriate reducing agent is one which participates in formation of a chiral complex with an appropriate chiral auxiliary to give a stereoselectively reduced product.
• Appropriate reducing agents are well known in the art and include but are not limited to borane tetrahydrofuran complex, and borane dimethyl sulfide complex, with borane dimethyl sulfide complex being preferred.
• 2-chlorocyclohex-2-en-l-one is contacted with a fractional molar amount of an appropriate chiral auxiliary, such as (S)-tetrahydro-l-methy-3,3-diphenyl- lH,3H-pyrrolo-[l,2C] [1,3,2]oxazaborole [D.J. Mathre et al. , J. Org. Chem. 5 ⁇ _, 751-762 (1991)] and a slight molar excess of an appropriate reducing agent.
• the amount of appropriate chiral auxiliary depends on the chiral auxiliary used and ranges from 0.05 to 0.5 molar equivalents.
• the reaction is carried out at a temperature that does not allow for the over reduction of the enone function and allows for the enantioselective reduction of the chiral auxiliary complex.
• the reaction is carried out in a suitable solvent, such as tetrahydrofuran or diethyl ether.
• a suitable solvent such as tetrahydrofuran or diethyl ether.
• the product may be isolated from the reaction zone by quenching the reaction with a protic solvent, such as methanol and extraction.
• the product may be used without further purification or may be purifying by methods well known in the art, such as chromatography and recrystallization.
• step c (R)-2-chloro-cyclohex-2-enylalcohol is contacted with trichloroacetonitrile to give (R)-2,2,2- ;richloro-l-( 2-chloro-cyclohex-2-enyloxy)-et- .'lideneamine.
• (R)-2-chloro-cyclohex-2-enylalcohol is contacted with a molar excess of trichloroacetonitrile.
• the reaction is carried in the presence of a catalytic amount of a ba ⁇ e, such as sodium hydride.
• a catalytic amount varies Dm 0.05 to 0.20 molar equivalents.
• the reaction is c -.ied out in a suitable solvent, such as tetrahydrofuran or ⁇ ethyl ether.
• the reaction is carried out at temperatures of from -20°C to 20°C , with 0°C being preferred.
• product may be isolated from the reaction zone by evaporation or extraction and may be used without further purification or may be purifying by methods well known in the art, such as chromatography and recrystallization.
• (R)-2,2,2-trichloro-l-(2-chloro-cyclohex- 2-enyloxy)-ethylideneamine is heated at a temperature of from 130°C to 150°C.
• the reaction is carried out in a suitable solvent, such as chlorobenzene.
• the product may be isolated from the reaction zone by evaporation or extraction and may be purifying by methods well known in the art, such as chromatography and recrystallization.
• step e (R)-2,2, 2-trichloro-N-( 2-chloro- cyclohex-2-enyl)-acetamide is treated with an appropriate solvolyzing agent to give (S)-2-chloro-cyclohex-2- enylamine.
• solvolysis agents are well known in the art, such as methanol, ethanol, and water.
• (S)-2,2,2-trichloro-N-(2-chloro-cyclohex- 2-enyl)-acetamide is contacted with water to give (S)-2- chloro-cyclohex-2-enylamine.
• the reaction may be carried out in a suitable solvent, such as ethanol, methanol, water, methanol/water mixtures, or ethanol/water mixtures.
• the reaction is promoted by the addition of a suitable base, such as potassium carbonate.
• the reaction is carried out at a temperature of from 50°C to 90°C with 70°C being preferred.
• the product may be used directly. When methanol/water mixtures or ethanol/water mixtures are used the product may be used directly after the removal of the alcohol solvent.
• the product may be isolated from the reaction zone by evaporation or extraction and may be used without further purification or may be purifying by methods well known in the art, such as chromatography and salt formation and recrystallization.
• step f (S)-2-chloro-cyclohex-2-enylamine is reacted with an appropriate phthalimido-L-phenyalanine derivative to give (S)-N-(2-chloro-cyclohex-2-enyl)-2- [2(S)-1,3-dihydro-l,3-dioxo-isoindol-2-yl)-3-phenyl- propionamide.
• An appropriate phthalimido-L-phenyalanine derivative is one that transfers the phthalimido-L-phenyalanine group, such as phthalimido-L-phenyalanine acid, phthalimido-L- phenyalanine acid anhydride, a phthalimido-L-phenyalanine acid mixed anhydride, phthalimido-L-phenyalanine acid chloride, or phthalimido-L-phenyalanine N- hydroxysuccinimide.
• phthalimido-L-phenyalanine acid such as phthalimido-L-phenyalanine acid, phthalimido-L- phenyalanine acid anhydride, a phthalimido-L-phenyalanine acid mixed anhydride, phthalimido-L-phenyalanine acid chloride, or phthalimido-L-phenyalanine N- hydroxysuccinimide.
• (S)-2-chloro-cyclohex-2-enylamine is contacted with an appropriate phthalimido-L-phenyalanine derivative.
• an appropriate phthalimido-L-phenyalanine derivative such as 1,3- dicyclohexylcarbodiimide or 2-ethyl-l-ethoxycarbonyl-l,2- dihydroquinoline.
• the reaction is carried out in the presence of a base, such as sodium carbonate, sodium bicarbonate, potassium carbonate, triethylamine, or potassium bicarbonate to neutralize the acid which is liberated during the course of the reaction.
• a base such as sodium carbonate, sodium bicarbonate, potassium carbonate, triethylamine, or potassium bicarbonate to neutralize the acid which is liberated during the course of the reaction.
• the reaction is carried out n suitable solvent, such as water, tetrahydrofuran, ethyl acetate, or ethyl acetate/ water mixtures.
• suitable solvent such as water, tetrahydrofuran, ethyl acetate, or ethyl acetate/ water mixtures.
• the reaction is carried out at a temperature of from -20°C to 40°C, with 0°C being preferred.
• the product may be isolat I from the reaction zone by extraction and evaporation, as is well known in the art.
• the product may be purified by techniques well known in the art, such as chromatography and recrystallization.
• step g (S)-N-(2-chloro-cyclohex-2-enyl)-2- [2(S)-l,3-dihydro-l,3-dioxo-isoindol-2-yl)-3-phenyl- propionamide is contacted with ozone in the presence of methanol to give after a reductive work-up N-[2(S)-[(6- oxo)-hexanoic acid methyl ester] ]-2-[2(S)-l,3-dihydro-l,3- dioxo-isoindol-2-yl)-3-phenyl-propionamide methyl ester.
• (S)-N-(2-chloro-cyclohex-2-enyl)-2-[2(S)- 1,3-dihydro-l,3-dioxo-isoindol-2-yl)-3-phenyl-propionamide is contacted with ozone in the presence of methanol.
• the reaction is carried out in a suitable solvent, such as dichloromethane.
• the reaction is carried out at a temperature of from -100°C to -60°C, with -70°C being preferred.
• the reaction is worked-up reductively by the addition of a suitable reducing agent, such as tributylphosphine or dimethyl sulfide.
• the product may be isolated from the reaction zone by evaporation and may be used without further purification.
• the product may be purified by techniques well known in the art, such as chromatography and recrystallization.
• N-[2(S)-[ (6-oxo)-hexanoic acid methyl ester] ]-2-[2(S)-l,3-dihydro-l,3-dioxo-isoindol-2-yl)-3- phenyl-propionamide is contacted with an appropriate cyclizing acid, such as trifluoroacetic acid.
• the reaction is carried out in a suitable aprotic solvent, such as methylene chloride.
• the reaction is carried out at the reflux temperature of the solvent.
• the reaction is carried out in such a way that the refluxate can be dried as it is formed, such as by the use of a Dean-Stark trap or by passing the refluxate through a bed of 3A or 4A molecular sieves.
• the product may be isolated by evaporation and may be purified by techniques well known in the art, such as chromatography and recrystallization.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Indole Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Peptides Or Proteins (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22557529

Family Applications (1)

Country Status (20)

Families Citing this family (1)

Family Cites Families (5)

• 1994
  • 1994-10-20 CA CA002177044A patent/CA2177044C/en not_active Expired - Fee Related
  • 1994-10-20 HU HU9601335A patent/HU220895B1/hu not_active IP Right Cessation
  • 1994-10-20 DK DK95900385.6T patent/DK0729456T3/da active
  • 1994-10-20 CN CN94194207A patent/CN1041627C/zh not_active Expired - Fee Related
  • 1994-10-20 NZ NZ275939A patent/NZ275939A/en not_active IP Right Cessation
  • 1994-10-20 JP JP51506295A patent/JP3547749B2/ja not_active Expired - Fee Related
  • 1994-10-20 AU AU81225/94A patent/AU683956B2/en not_active Ceased
  • 1994-10-20 DE DE69407430T patent/DE69407430T2/de not_active Expired - Lifetime
  • 1994-10-20 ES ES95900385T patent/ES2112034T3/es not_active Expired - Lifetime
  • 1994-10-20 AT AT95900385T patent/ATE161251T1/de active
  • 1994-10-20 WO PCT/US1994/011941 patent/WO1995014663A2/en not_active Ceased
  • 1994-10-20 EP EP95900385A patent/EP0729456B1/en not_active Expired - Lifetime
  • 1994-10-20 KR KR1019960702648A patent/KR100310592B1/ko not_active Expired - Fee Related
  • 1994-10-20 FI FI962045A patent/FI962045A0/fi unknown
  • 1994-11-14 ZA ZA949030A patent/ZA949030B/xx unknown
  • 1994-11-15 TW TW083110598A patent/TW321638B/zh not_active IP Right Cessation
  • 1994-11-16 IL IL11165694A patent/IL111656A/xx not_active IP Right Cessation
• 1995
  • 1995-03-30 US US08/415,028 patent/US5502253A/en not_active Expired - Lifetime
• 1996
  • 1996-03-30 US US08/413,649 patent/US5508411A/en not_active Expired - Lifetime
  • 1996-05-15 NO NO961999A patent/NO309269B1/no not_active IP Right Cessation
• 1998
  • 1998-01-14 GR GR980400072T patent/GR3025899T3/el unknown

Also Published As

Similar Documents

Legal Events